Caris MPI, Inc. v. Foundation Medicine, Inc. (17-cv-12194).

Caris filed suit asserting that Foundation Medicine’s FoundationOne®, FoundationOne® Heme, and FoundationACT® products infringe five Caris patents covering systems for generating reports identifying therapeutic agents for cancer treatment based on molecular profiles of the tumor. Caris alleges willful infringement, citing to statements in Foundation’s 10-K SEC filings that identify Caris as a direct competitor and that indicates that competitors “may also use their patent portfolios, developed in connection with developing their tests, to allege that [Defendant’s] products infringe their patents, and [Defendant] could face litigation with respect to such allegations and the validity of such patents.”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s